These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. Bigira V; Kapisi J; Clark TD; Kinara S; Mwangwa F; Muhindo MK; Osterbauer B; Aweeka FT; Huang L; Achan J; Havlir DV; Rosenthal PJ; Kamya MR; Dorsey G PLoS Med; 2014 Aug; 11(8):e1001689. PubMed ID: 25093754 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Assefa DG; Zeleke ED; Bekele D; Tesfahunei HA; Getachew E; Joseph M; Manyazewal T Malar J; 2021 Apr; 20(1):174. PubMed ID: 33794897 [TBL] [Abstract][Full Text] [Related]
13. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens. Kapisi J; Bigira V; Clark T; Kinara S; Mwangwa F; Achan J; Kamya M; Soremekun S; Dorsey G Malar J; 2015 Feb; 14():53. PubMed ID: 25652127 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. Cisse B; Cairns M; Faye E; NDiaye O; Faye B; Cames C; Cheng Y; NDiaye M; Lô AC; Simondon K; Trape JF; Faye O; NDiaye JL; Gaye O; Greenwood B; Milligan P PLoS One; 2009 Sep; 4(9):e7164. PubMed ID: 19784374 [TBL] [Abstract][Full Text] [Related]
16. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. Sambol NC; Tappero JW; Arinaitwe E; Parikh S PLoS One; 2016; 11(5):e0154623. PubMed ID: 27182702 [TBL] [Abstract][Full Text] [Related]
17. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649 [TBL] [Abstract][Full Text] [Related]
18. Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. Kwambai TK; Dhabangi A; Idro R; Opoka R; Kariuki S; Samuels AM; Desai M; van Hensbroek MB; John CC; Robberstad B; Wang D; Phiri K; Ter Kuile FO Trials; 2018 Nov; 19(1):610. PubMed ID: 30400934 [TBL] [Abstract][Full Text] [Related]
19. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242 [TBL] [Abstract][Full Text] [Related]
20. Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali. Traore K; Coulibaly D; Kone AK; Guindo B; Traore S; Kouriba K; Djimde M; Thera MA J Infect Dis; 2024 Jan; 229(1):189-197. PubMed ID: 37682871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]